Home – CDMO Solutions | Viral Vectors | AAV
Accelerated AAV manufacturing with industry-leading performance
OXB delivers fast, flexible, and high-performance AAV manufacturing solutions to support advanced therapy developers worldwide. Our proprietary inAAVateTM platform can deliver GMP AAV in as little as 7 months and consistently achieves high titres and market leading full-to-empty capsid ratios. Alongside platform projects, clients can also tech transfer-in to OXB or work with us on a custom project.
OXB’s AAV track record
0+
GMP batches successfully released
0
Successful regulatory submissions
0
monthsTo GMP release
0E+
17vgsAt 500L scale
0%
Full capsids
0%
Analytical assays performed in-house
inAAVate™ platform
Accelerating AAV success from design to GMP
OXB’s inAAVate™ platform provides a robust, standardised foundation to help partners achieve clinical and commercial milestones faster. Our end-to-end platform integrates proprietary technologies across construct design, upstream and downstream processing, analytics, and fill/finish.
Clients can access the Triple Plasmid, or Dual Plasmid System, which together with our proprietary transfection process are responsible for increasing bioreactor vg titre up to 10-fold over typical industry standards.
With the inAAVate™ platform, clients can progress from project initiation to their first GMP batch in as little as 7 months.
Explore the inAAVate™ platform
Our platform technologies:
Related resources
An Engineered Helper Plasmid Generates Differential E4orf6 and L4-22/33K Gene Expression Increasing AAV Vector Production
Discover how engineered helper plasmids can increase AAV yields by up to fivefold while preserving vector quality, offering a scalable approach to more efficient AAV manufacturing.
View PDF >Podcast: Building quality at scale – How viral vector CDMOs stay inspection ready
Melanie Kearney, SVP and Global Head of Quality explores how connecting R&D and manufacturing earlier can prevent delays and unnecessary complexity, why audits don’t have to be something to “get through” but can actually become a competitive advantage, and how clear communication and continuous improvement help turn change into opportunity.
View details >5 Questions with… Ceri Schofield
How can Quality accelerate programme success while reducing risk? In this edition of 5 Questions with..., Ceri Schofield, VP and Head of Quality at OXB, shares her perspective on the increasingly strategic role of Quality in viral vector development.
View PDF >5 Questions with… Melanie Kearney
Quality is about more than compliance. It's about building confidence at every stage of development. In this edition of 5 Questions with..., Dr. Melanie Kearney, SVP, Global Head of Quality at OXB, explores why Quality should be embedded from the very beginning of a cell and gene therapy programme.
View PDF >
Structural Analysis of Recombinant AAV Vector Genomes at Single-Molecule Resolution
This paper presents a long-read analysis pipeline for accurately classifying recombinant AAV genome heterogeneity to improve vector characterization and design.
View PDF >AAV: Novel Dual-Plasmid Transfection System
This brochure introduces OXB's novel dual plasmid transfection system for AAV development and manufacture.
View PDF >Why choose OXB as your AAV CDMO?
Accelerating AAV Success from design to GMP
Reach GMP in as little as 7 months
By leveraging the inAAVateTM plug-and-play platform process, the need for excessive process development is eliminated, allowing clients to reach GMP in as little as 7 months.
Maximise commercial viability with more doses per batch
By continually developing innovative technologies, OXB clients can now achieve titres of 1.5E+17vgs from a 500L bioreactor, with 90% full capsids, delivering cost efficiencies through more doses per batch.
Effectively manage budgets and milestones
Our flexible delivery and commercial models ensure clients can effectively manage budgets in line with funding milestones and decision points.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
Frequently asked questions
In comparison to the traditional triple plasmid system, OXB’s dual plasmid system combines Rep Cap and GOI into one plasmid without impacting the DNA sequence. Together with our proprietary transfection process, the dual-plasmid system increases bioreactor titre 10-fold and can reduce the overall cost per dose.
OXB has a proven track record in supporting global regulatory filings, including 30+ successful IND submissions and 2 BLA/MAA submissions. We continuously interact with regulatory bodies and provide expert consultation on CMC dossiers, respond to regulatory questions, and provide regulatory advice on the optimum selection of assays.
OXB performs 90% of analytical assays in-house, covering 40+ analytical methods across biological activity, identity, purity, quantity and safety. We utilize 24 routine methods to test product quality on every lot.
OXB has experience with a wide range of AAV serotypes, including some of the most common natural and engineered serotypes used in cell and gene therapy. We have produced over 2,000 batches with multiple serotypes and have significant experience with novel and challenging serotypes to package and purify. Please get in touch to discuss your specific serotype.
OXB offers a number of pathways to GMP with the flexibility to meet specific client needs. These typically range from 7 to 12 months, dependent on plasmid availability, cloning requirements and the level of regulatory data needed.
Platform feasibility in just 6 weeks
For early-stage clients and those that require drug substance for in vitro or in vivo studies, we offer a cost-effective platform feasibility project, including analytics, in just 6 weeks. Test your gene of interest (GOI) in the inAAVateTM platform.
